SpectraScience Inc. (OTCBB: SCIE), a developer of light-based diagnostic systems for cancer identification, similar to companies like Verisante Technology Inc. (CVE: VRS) and MELA Sciences Inc. (NASDAQ: MELA), recently announced that it has begun sales training with its partner PENTAX Europe in Germany and Belgium following its technician training program.

The sales training is aimed at raising awareness of the WavSTAT units at hospitals in several European countries, where the company has already seen an enthusiastic start, according to CEO Michael Oliver. The move paves the way for near-term revenues for the company from not only the base units, but the disposables that provide a recurring revenue stream over time.

In addition to the sales training, WavSTAT technology was demonstrated in the PENTAX booth at the German Society of Digestive and Metabolic Disease Conference in Hamburg, September 19-22. The conference was attended by leading gastroenterologists and abdominal surgeons, and represented the first opportunity to feature WavSTAT at a major professional event in Germany.

“Our sales training program in Europe is off to a terrific start, and we are moving forward in other countries in the next few weeks,” said Michael Oliver, SpectraScience’s Chief Executive Officer. ”The PENTAX Europe sales force is very enthusiastic regarding the prospects for WavSTAT, and the conference audience regarded it as an important addition to the PENTAX product portfolio. We believe WavSTAT will generate new revenue for PENTAX in existing accounts and, perhaps more importantly, also provide access to competitive accounts seeking a unique technology.”

About SpectraScience, Inc.

SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With approval for sale under the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.

Forward-Looking Statements

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company’s products and services in the marketplace, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.